Pathologic response to neoadjuvant sequenced, lymphatic-sparing SBRT plus pembrolizumab in HPV-negative head and neck squamous cell carcinoma.
R. Bryan Bell(Takara (United States)), Marka R. Crittenden(Providence Portland Medical Center), Robert Saddawi‐Konefka(The University of Texas MD Anderson Cancer Center), Joseph A. Califano(University of California San Diego), Matthew H. Taylor(Providence Portland Medical Center), J. Silvio Gutkind(National Institutes of Health), Thomas Duhen(AGCO (Netherlands)), Michael J. Gough(Providence Portland Medical Center), Andrew B. Sharabi(UC San Diego Health System), Kristina H. Young(Providence Portland Medical Center), Rom S. Leidner(Providence Portland Medical Center), Bernard A. Fox(Oregon Health & Science University), Ashish Patel(Providence Portland Medical Center), Douglas Hanes(Providence Portland Medical Center), Brian Piening(Providence College), Hong Xiao(Fujian Medical University), Robert Michael Hermann(Providence Portland Medical Center), Liza Blumenfeld(UC San Diego Health System), Ezra E.W. Cohen(Moores Cancer Center), Steven K. Seung(Providence Portland Medical Center)
Cited by 2
Related Papers
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i>
|Science|2011|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight
|Science|2019|1.1k
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
|Nature Communications|2018|927
Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice
|Journal of Clinical Investigation|2002|915